Company description
The American Chamber of Commerce in the Netherlands (AmCham) is a non-profit, non-governmental, non-political, voluntary organization of companies and individuals who invest in and trade between the United States of America and the Netherlands. The Netherlands is one of the most important destinations for US direct investment in Europe and a major hub of American professionals living and working abroad.
Products and services
American and Chamber member companies employ over 1.3 million people in the Netherlands. Of these, minority and majority owned American companies directly employ over 210,000 people and are the source of almost 5 percent of the country’s GNP. On a historical-cost basis the total US direct investment position in the Netherlands in 2008 totaled over $440 billion (source: US Dept. of Commerce, Bureau of Economic Analysis). Total assets of US non-bank foreign affiliates in the Netherlands were estimated to total over $1.18 trillion in 2007. Over the past decade alone, US direct investment flows have totaled over $250 billion. American business has had good reason to come to the Netherlands in the past and the Chamber works to ensure they have good reason to stay in the future.
Many Dutch Chamber members are significant investors in the United States. Well over $250 billion of investment has flowed from the Netherlands to the United States – making the Netherlands the fourth largest foreign investor in the US. The common denominator shared by all our members is a belief in the importance of two-way trade and investment between the Netherlands and the United States as an essential basis for creating mutual economic welfare.
Established in 1961 and now in its fifth decade of service to the US business community, the American Chamber of Commerce in the Netherlands seeks to further the development of commerce between the United States of America and the Netherlands. AmCham Netherlands encourages and facilitates the transaction of business between both countries and promotes the interests of its members in matters of trade and investment.
Contact
American Chamber of Commerce in the Netherlands
P.O. Box 15783
1001 NG Amsterdam
Tel: +31 (0)20 7951840
Fax: +31 (0)20 7951850
Email: office@amcham.nl
Michel van Agthoven outlines the role played by the Pharmaceutical Committee of the American Chamber in contributing to healthcare related policies in the Netherlands through research programs and by encouraging…
How do you operate in terms of the stakeholder management, with all of your associate members? Do you tend to operate from the committee perspective, or is there an annual…
Given the peculiarities of the pharmaceutical industry in the Netherlands, such as the highest generics penetration rate in Europe, a relatively small manufacturing presence and a considerably regulated market, what…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an…
Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager…
See our Cookie Privacy Policy Here
